目的 探討芪藶強心膠囊聯(lián)合環(huán)磷腺苷葡胺治療慢性心力衰竭的臨床療效。方法 選擇衡水市第五人民醫(yī)院內(nèi)科2013年2月-2015年2月收治的慢性心力衰竭患者82例,隨機分為治療組和對照組,每組各41例。對照組在常規(guī)治療的基礎(chǔ)上靜脈滴注環(huán)磷腺苷葡胺注射液120 mg,1次/d。治療組在對照組的基礎(chǔ)上服用芪藶強心膠囊,4粒/次,3次/d。兩組療程均為2個月。比較兩組的臨床療效、6分鐘步行距離(6MWD)、左室射血分數(shù)(LVEF)以及心衰生化指標肌鈣蛋白T(cTnT)、氨基末端B型腦利鈉肽前體(NT-proBNP)、血清類胰島素生長因子-1(IGF-1)、高敏C反應蛋白(hs-CRP)和同型半胱氨酸(Hcy)。結(jié)果 治療組總有效率(95.12%)明顯高于對照組(80.48%),兩組比較差異具有統(tǒng)計學意義(P < 0.05);治療后,兩組的6MWD、LVEF顯著高于同組治療前,且治療組高于對照組,兩組比較差異具有統(tǒng)計學意義(P < 0.05)。治療后,兩組的cTnT、NT-proBNP、hs-CRP、Hcy顯著低于同組治療前,IGF-1顯著高于治療前,且比較差異有統(tǒng)計學意義(P < 0.05);治療后,治療組的cTnT、NT-proBNP、hs-CRP、Hcy顯著低于對照組,IGF-1顯著高于對照組,且比較差異具有統(tǒng)計學意義(P < 0.05)。結(jié)論 芪藶強心膠囊聯(lián)合環(huán)磷腺苷葡胺治療慢性心衰具有較好的臨床療效,且能夠改善慢性心衰的觀察指標。

Objective To investigate the clinical effect of Qili Qiangxin Capsules combined with meglumine adenosine cyclophosphate in treatment of chronic heart failure. Methods Patients (82 cases) with chronic heart failure in the Fifth People's Hospital of Hengshui from February 2013 to February 2015 were randomly divided into control and treatment groups. Each group had 41 cases. Patients in control group were iv Meglumine Adenosine Cyclophosphate Injections on the basis of conventional therapy 120 mg, once dialy. Patients in treatment group were given Qili Qiangxin Capsules 4 pills/time, three times daily. The patients in two groups were treated for 2 months. The efficacy, 6-minute walk distance (6MWD), left ventricular ejection fraction (LVEF), and biochemical indicators of heart failure cardiac troponin (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP), insulin-like growth factor-1 (IGF-1), high-sensitivity C-reactive protein (hs-CRP) and homocysteine (Hcy) between patients of two groups were compared. Results The clinical efficacy in treatment group (95.12%) was higher than that in control group (80.48%) with significant difference (P < 0.05). After treatment, 6MWD and LVEF were significantly higher than those of same group before treatment. And 6MWD and LVEF in treatment group were higher than those in control group, and the difference was statistically significant (P < 0.05). After treatment, the levels of cTnT, NT-proBNP, hs-CRP, and Hcy of two groups were significantly lower than those before treatment with significant differences (P < 0.05). The level of IGF-1 was significantly higher than that before treatment with significant difference (P < 0.05). The levels of cTnT, NT-proBNP, hs-CRP, and Hcy were significantly lower than those in control group, and the level of IGF-1 was significantly higher than that control group with significant difference (P < 0.05). Conclusion Qili Qiangxin Capsules combined with meglumine adenosine cyclophosphate has good efficacy in treatment of chronic heart failure, and can greatly improve the obvervational index of chronic heart failure.

衡水市科技計劃項目(201433Z)